P072 Activity and clinical outcomes of New Agents (NAs) administered as third or fourth line after the failure of docetaxel (DOC) and another NA in metastatic Castration-Resistant Prostate Cancer (mCRPC) patients. Final results of an Italian multicentre retrospective study
2014
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
0
References
3
Citations
NaN
KQI